New combo pill for high blood pressure put to the test

NCT ID NCT06884085

Completed Knowledge-focused Sponsor: Addpharma Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new drug called AD-227 in 70 healthy adults. Researchers wanted to see if taking a single combination tablet works as well as taking two separate pills (AD-227A and AD-227B) in terms of safety and how the drug moves through the body. The study is already completed, but results are not yet available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AD-227 (a combination tablet of AD-227A and AD-227B)
What this could lead to: If successful, this study could show that a single combination tablet works as well as taking two separate pills, potentially simplifying treatment for high blood pressure.
What could go wrong: This is an early Phase 1 trial in only 70 healthy volunteers, not patients with high blood pressure. It measures drug levels and safety, not whether the drug actually lowers blood pressure. Many early-stage drugs fail to show benefit in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY HYPERTENSION

Contacts and locations

Locations

Central Hospital

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.